Odisha Approves Pharma & MedTech Policy to Build Sector Hubs & Boost Investment

The new policy will help Odisha build a competitive ecosystem for pharmaceutical and MedTech manufacturing, offering investors modern infrastructure, incentives and streamlined approvals to scale operations.

The Odisha Cabinet has approved a new Pharma & MedTech Policy designed to position the state as a competitive hub for pharmaceutical manufacturing, medical device production, and healthcare innovation.

The policy is expected to drive large-scale investment and accelerate the development of sector-specific industrial clusters equipped with advanced infrastructure and streamlined regulatory processes.

Announcing the approval, Chief Secretary Pradeep Kumar Jena said the new policy will give Odisha a stronger presence in India’s expanding healthcare manufacturing landscape. “The Pharma and MedTech sector have significant potential for growth,” he noted.

Adding that the policy aims to support investors with incentives, land availability and plug-and-play facilities to help companies scale faster.

The initiative includes the creation of dedicated industrial hubs to attract pharmaceutical companies, bulk drug manufacturers, diagnostic device producers and MedTech innovators.

Industries Secretary Hemant Sharma highlighted that the policy is designed to help Odisha tap into rising demand for domestic manufacturing. “We see this as an opportunity to build a reliable, high-quality ecosystem that supports both innovation and large-scale production,” he said.

By expanding manufacturing capacities within the state, Odisha aims to strengthen supply chains and provide a conducive environment for research, technology upgrades and global export opportunities.

The Cabinet also emphasized the policy’s potential to create high-skilled employment and foster industry-academia collaboration across pharmaceuticals and MedTech.

Hemant Sharma mentioned the state is prepared to offer investor-friendly support. “Our focus is on creating long-term value for companies and ensuring Odisha becomes a preferred destination for the life sciences sector.”

With the policy now in place, the government is expected to initiate development work within planned industrial zones and begin outreach to domestic and international manufacturers.

Related Posts

Over 9,000 deaths due to respiratory diseases in Delhi

New Delhi:  The national capital recorded 9,211 deaths due to respiratory diseases in 2024, up from 8,801 in 2023, continuing an upward trend seen over the past few years, according…

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

New Delhi:  The demand for nebulisers, inhalers and respiratory medicines for children has surged sharply in Delhi during winter months, with chemists reporting spikes of up to 60 per cent…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Over 9,000 deaths due to respiratory diseases in Delhi

Over 9,000 deaths due to respiratory diseases in Delhi

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

Pharma company, its employees convicted for ‘illegal diversion” of meth precursor abroad

Pharma company, its employees convicted for ‘illegal diversion” of meth precursor abroad

Ayurveda practitioner fined by ISM Council for violation of professional ethics

Ayurveda practitioner fined by ISM Council for violation of professional ethics

Administering rabies vaccine at the wrong site can be fatal: Shoulders or thighs only, warn experts

Administering rabies vaccine at the wrong site can be fatal: Shoulders or thighs only, warn experts

Delhi HC allows Zydus to sell biosimilar of blockbuster anti-cancer drug Nivolumab

Delhi HC allows Zydus to sell biosimilar of blockbuster anti-cancer drug Nivolumab